Startseite
Märkte
Charts & Ideen
Algo
Nachrichten
Store
Broker
Herunterladen
Wirtschaftskalender
Handelssignale
WebTerminal
Geben Sie
/
ein, um zu suchen: @user, $symbol
Suche
Einloggen
Eröffnen Sie ein Konto
Deutsch
English
Русский
中文
Español
Português
日本語
한국어
Français
Italiano
Türkçe
IMCR
#1803
Immunocore Holdings plc American Depositary Shares
32.300
0
+2.28%
Sektor:
Basis:
Gewinnwährung:
Tagesspanne
Jahresspanne
Tagesänderung
+2.28%
Monatliche Änderung
-8.00%
6 month change
-3.52%
Jahresänderung
-3.52%
Vorheriger Schlusskurs
31.580
0
Open
32.300
0
Bid
Ask
Low
32.300
0
High
32.300
0
Volumen
17
Märkte
Aktien
Gesundheitswesen
IMCR
Open full chart
Financials
Overview
Finanzbericht
Statistics
Dividends
Quarterly
Annual
Income statement
Balance sheet
Cash flow
Value
2020
2021
2022
2023
2024
2025
Total assets
—
—
—
597 M
1.01 B
1.07 B
Total liabilities
—
—
—
228.16 M
648.79 M
686.24 M
Total equity
—
—
—
368.84 M
360.72 M
381.03 M
Total liabilities & shareholders' equities
—
—
—
597 M
1.01 B
1.07 B
Total debt
—
—
—
—
—
—
Net debt
—
—
—
—
—
—
Immunocore Holdings plc - American Depositary Shares
Immunocore is a global commercial-stage biotechnology company, based in Oxfordshire, which researches and develops biological drugs using soluble T-cell receptor technology.
Nachrichten
Immunocore Holdings plc 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:IMCR) 2026-02-25
Immunocore Holdings plc (IMCR) Q4 2025 Earnings Call Transcript
Immunocore Holdings: EPS verfehlt Schätzungen um 0,40 $ - Umsatz schlechter als erwartet
Immunocore Holdings earnings missed by $0.40, revenue fell short of estimates
JAZZ Stock Rises as Q4 Earnings & Sales Top Expectations
RXRX Q4 Loss Narrower Than Expected, Revenues Increase Y/Y, Stock Up
Repligen's Q4 Earnings Beat Estimates, Revenues Surge Y/Y
Apellis Q4 Loss Wider Than Expected, Revenues Decline Y/Y
Immunocore vor Quartalszahlen: Melanom-Pipeline im Fokus der Anleger
Immunocore earnings ahead as melanoma pipeline advances
Madrigal Q4 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Down
Immunocore (IMCR) Upgraded to Strong Buy: Here's Why